The use of biomarkers in diagnosis, therapy and prognosis has gained increasing interest
over the last decades. In particular, the analysis of biomarkers in cancer patients within the …

Immuno-oncology approaches have entered clinical practice, with tremendous progress
particularly in the field of T cell-engaging therapies over the past decade. Herein, we provide …

Approximately 50% of acute myeloid leukemia (AML) patients do not respond to induction
therapy (primary induction failure [PIF]) or relapse after< 6 months (early relapse [ER]). We …

Harnessing the power of immune cells, especially T cells, to enhance anti-tumor activities
has become a promising strategy in clinical management of hematologic malignancies. The …

TP53-mutated myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) form a
distinct group of myeloid disorders with dismal outcomes. TP53-mutated MDS and AML …

T-cell-engaging bispecific antibodies (BsAbs) simultaneously bind to antigens on tumour
cells and CD3 subunits on T cells. This simultaneous binding results in the recruitment of T …

The β common chain cytokines GM-CSF, IL-3, and IL-5 regulate varied inflammatory
responses that promote the rapid clearance of pathogens but also contribute to pathology in …

Background The T-cell receptor (TCR), located on the surface of T cells, is responsible for
the recognition of the antigen-major histocompatibility complex, leading to the initiation of an …

Bispecific antibodies (bsAbs) enable novel mechanisms of action and/or therapeutic
applications that cannot be achieved using conventional IgG-based antibodies …

Opinion statement Approximately 40–45% of younger and 10–20% of older adults with
acute myeloid leukemia (AML) will be cured with current standard chemotherapy. The …